BioTech
All initial communications will be channeled through Flusso Capital to maintain a streamlined and effective investment process for all stakeholders.
Found a Company You Like? Request More Information← Investor PortalBT759112
Transforming the future of aging and neurodegenerative disease treatment by developing gene therapies that restore youthful cellular function. Unlike conventional treatments that only manage symptoms, its tissue-specific gene therapies use partial cellular reprogramming to reset gene expression, directly reversing the biological processes that drive Alzheimer’s and other age-related diseases.
With a $550B market opportunity, an aging global population, and growing demand for disease-modifying treatments, the company is positioned at the forefront of the longevity and regenerative medicine revolution. Its breakthrough therapies have demonstrated significant cognitive restoration in preclinical models, offering a potentially curative approach to neurodegeneration—a massive unmet need in the healthcare industry.
Backed by exclusive partnerships with world-renowned researchers, a strong intellectual property portfolio, and a clear regulatory path toward clinical trials, the company is raising $10M to advance IND-enabling studies, GMP manufacturing, and further pipeline development. This is a rare opportunity to invest early in a high-impact biotech with first-mover advantage in a trillion-dollar industry.
BT457321
Transforming cancer treatment by introducing a non-invasive, AI-powered therapy that offers a breakthrough alternative to traditional chemotherapy and radiation. By leveraging oxygen therapy, peptides, IV-based treatments, and cutting-edge AI diagnostics, the company provides a painless, highly effective cancer treatment with a 70% success rate. Unlike conventional therapies that cause debilitating side effects, this approach is designed to enhance patient outcomes, improve quality of life, and make advanced cancer care more accessible.
With a $280B market opportunity, the oncology sector is rapidly shifting toward personalized, data-driven treatments, and this company is at the forefront of that transformation. Its AI-powered precision medicine platform enables early detection, tailored treatment plans, and scalable telehealth integration, making it a first-mover in a fast-growing market.
The company has already secured early traction with hospital partnerships and is positioned for rapid expansion. Now raising $2M to scale operations, refine its AI diagnostics, and accelerate market adoption, this is a unique opportunity to invest in the future of cancer care—an innovative, high-growth biotech that is redefining how cancer is treated worldwide.
BT275916
Chronic kidney disease is a $95B+ market with limited treatment options, and current therapies fail to address the root cause—cellular aging. This company is solving this with an AI-driven drug discovery platform that develops safer, more effective molecules to clear senescent kidney cells and reverse disease progression.
Unlike competitors struggling with off-target toxicity, its proprietary AI/ML-designed molecules enhance safety, metabolism, and bioavailability, dramatically increasing clinical success rates. With exclusive partnerships, a strong patent portfolio, and successful preclinical results in reversing disease progression in models, the company is positioned as the first to truly halt and reverse kidney disease at a cellular level.
Currently raising funds to advance IND-enabling studies and prepare for clinical trials, this is an opportunity to invest early in a biotech with massive acquisition potential in a billion-dollar market underserved by Big Pharma.
BT945680
The diagnostics industry is overdue for disruption, with outdated and inefficient testing methods limiting real-time treatment optimization. This company has developed a revolutionary biosensor platform that enables rapid, scalable, and highly specific drug and biomarker detection, dramatically improving diagnostics for metabolic health, chronic pain, and impairment testing.
Unlike traditional diagnostics that rely on costly, slow, and often imprecise methods, this company’s yeast-based receptor-binding assays use AI-enhanced biosensors to detect active drug metabolites and physiological responses in real-time—transforming how treatments are prescribed, optimized, and monitored.
With strong intellectual property, partnerships with leading research institutions, and a clear path to commercialization across multiple billion-dollar markets, the company is currently raising funds to accelerate regulatory approvals and market entry. This is a rare opportunity to invest early in a company positioned to redefine diagnostic precision across multiple industries.
BT102161
The genetic data industry is broken—big corporations profit from consumer DNA while individuals have no control or financial benefit from their most personal asset. This company is changing the game with a blockchain-secured platform that gives people full ownership of their genetic data, allowing them to monetize it on their terms while providing researchers access to high-quality, precision-selected genomic data.
Unlike existing DNA platforms that exploit user data with hidden terms and zero transparency, this company’s decentralized AI-driven approach ensures privacy, security, and direct profit-sharing for individuals. Researchers also benefit from granular control over data selection, enhancing research efficiency and scientific breakthroughs.
With a $40B+ market opportunity, rapidly increasing demand for high-quality genomic data, and growing public distrust in centralized DNA testing services, the company is positioned to disrupt the space. Currently raising funds to accelerate commercial launch, this is a rare chance to invest early in the future of ethical and secure genetic data monetization.
BT424900
The $273B skincare market is filled with generic products that fail to address individual biological needs. This company is redefining skincare at the molecular level by integrating AI-powered compound screening, genetic insights, and epigenetic research to develop truly personalized treatments that reverse skin aging, repair DNA damage, and enhance long-term skin health.
Unlike traditional skincare brands that rely on one-size-fits-all formulations, this company’s proprietary technology analyzes skin age and genetic markers to create customized, high-performance solutions tailored to each individual’s biology. With exclusive IP, scientific backing from leading researchers, and a strong first-mover advantage in biotech-driven beauty, it is poised to disrupt the market.
Currently raising funds to accelerate clinical validation and commercialization, this is a rare opportunity to invest early in the future of precision skincare—where science, AI, and genetics converge to deliver results traditional brands simply cannot match.